TriSalus Life Sciences Inc. (TLSI) Next Earnings Date & Expected ±11.8% Move

$3.86 -1.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.84

TriSalus Life Sciences Inc. (TLSI) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $237.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TLSI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TLSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, TriSalus Life Sciences Inc. (NASDAQ: TLSI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.86 (-1.78% 1D, market cap $237.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TLSI ranks #808 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TLSI compare to BDSX and XGN in the Health Care sector?
▼

Within the Health Care sector (Medical Specialities), TLSI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 84.6%, and ROIC of -35.0%. By comparison, BDSX (Biodesix Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M) and XGN (Exagen Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $210.8M). Among the 5-stock peer group, TLSI leads on earnings multiple (N/A) while YDES leads on capital efficiency (-20.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TLSI?
▼

Per TLSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001826667), TriSalus Life Sciences Inc. generated $45.2M in revenue (+53.4% YoY), -$39.2M in net income, and -$18.9M in free cash flow against $35.3M in total assets and $33.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.84 (-0.51%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (9)Whales (4)SEC (11)Macro (4)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.2% Base Target
$8 Bull$3 Base$3 Bear
📬 FREE TLSI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TLSI)Realized 20D OHLCV Swing Band: ±11.8%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY TLSI SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (35% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (29% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 84.6% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$4.14-14.7% Next Q
Q2 (-2Q)
36
Grade E$3.53+2.5% Next Q
Q3 (-1Q)
34
Grade E$3.62+6.6% Next Q
Current
31
Grade E$3.86-9.4% Hist 90D α
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TLSI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TLSI currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.40) and Max Pain ($4.05) forces dealer call-delta covering toward $8.35.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TLSI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TLSI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±11.8% Swing Band

±$0.46 Expected Swing
$3.40 (-11.8%)Spot $3.86$4.32 (+11.8%)
MODEL EARNINGS SETUP GAUGE

TLSI Quantitative Pre-Earnings Setup: 31/100

Trailing EPS: $4.25 • YoY Revenue Growth: 53.4%

Model Bullish Setup (31/100)Model Risk Weight (69/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$45.2M-$39.2M-$18.9M84.6%
FY 20242024-12-31$29.4M-$30.0M-$41.2M86.1%
FY 20232023-12-31$18.5M-$59.4M-$50.6M84.6%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TLSI)

  • ✓Walkthrough of TLSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TLSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.26%▼ DESCENDING CHANNEL
2026-11-02O $3.93H $3.93L $3.86C $3.86VOL 113.9K
RES: $5.75SUP: $3.50SMA50: $4.40SMA200: $4.39
$6.17$5.09$4.02$2.94$1.87RES $5.75SUP $3.50$3.862026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TLSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +53.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TLSI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TLSI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TLSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TLSI)

Health Care Rank #808 of 1016 ⚔️ BDSX vs TLSI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TLSI vs. BDSX, XGN, YDES, BNR)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, TriSalus Life Sciences Inc. (TLSI) ranks #808 by composite RQD confidence (31/100, grade E) and #555 by equity capitalization ($237.7M). Within this direct 5-issuer industry benchmark cohort, TLSI leads on earnings valuation at N/A trailing P/E, while YDES leads on capital efficiency and profitability with -20.0% ROIC and 28.1% gross margin. YDES currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with TLSI at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TLSI ACTIVE
TriSalus Life Sciences Inc.
E 31/100 — 84.6% -35.0% -1.78% $237.7M Benchmark Subject
BDSX
Biodesix Inc.
D- 42/100 — — -35.0% +8.14% $260.8M /bdsx-vs-tlsi →
XGN
Exagen Inc.
D- 36/100 — 58.3% -35.0% +3.57% $210.8M /xgn-vs-tlsi →
YDES
YD Bio Limited
D 44/100 — 28.1% -20.0% -6.53% $415.8M /ydes-vs-tlsi →
BNR
Burning Rock Biotech Limited
E 20/100 — 74.7% -35.0% -9.87% $116.5M /bnr-vs-tlsi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001826667

In its most recent audited fiscal period (FY2025, filed 2025-12-31), TriSalus Life Sciences Inc. (TLSI) reported GAAP revenue of $45.2M (+53.4% vs. FY2024 revenue of $29.4M , and +143.9% cumulative change since FY2023) , GAAP net income of -$39.2M, operating cash flow of -$18.0M, and free cash flow of -$18.9M (+54.0% YoY). On the balance sheet, TLSI closed FY2025 with $35.3M in total assets against $33.0M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $45.2M -$39.2M -$18.0M -$18.9M $35.3M $33.0M
FY2024 (FY) 2024-12-31 $29.4M -$30.0M -$40.8M -$41.2M $24.0M $22.1M
FY2023 (FY) 2023-12-31 $18.5M -$59.4M -$50.6M -$50.6M — —

3. TLSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TLSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, TriSalus Life Sciences Inc. (NASDAQ: TLSI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.86 (-1.78% 1D, market cap $237.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TLSI ranks #808 in composite RQD confidence.

How does TLSI compare to BDSX and XGN in the Health Care sector?

Within the Health Care sector (Medical Specialities), TLSI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 84.6%, and ROIC of -35.0%. By comparison, BDSX (Biodesix Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M) and XGN (Exagen Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $210.8M). Among the 5-stock peer group, TLSI leads on earnings multiple (N/A) while YDES leads on capital efficiency (-20.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TLSI?

Per TLSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001826667), TriSalus Life Sciences Inc. generated $45.2M in revenue (+53.4% YoY), -$39.2M in net income, and -$18.9M in free cash flow against $35.3M in total assets and $33.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TLSI trading relative to its 50-day, 200-day, and 52-week technical levels?

TLSI last traded at $3.86 (-1.78% on volume of 113,864 shares), positioning the stock -12.27% below its 50-day simple moving average ($4.40) and -12.07% below its 200-day simple moving average ($4.39). Across its 52-week range of $2.20 to $7.95, TLSI sits at the 28.9% percentile with a 14-day RSI of 44.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.8% ($3.40 to $4.32).

TLSI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is TLSI's next earnings date?

Based on SEC filing cadence, TriSalus Life Sciences Inc. (TLSI)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is TLSI stock expected to move on earnings?

Volatility modeling currently projects a ±11.8% event move for TLSI, spanning a range between $3.4 and $4.32.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $213.66 -0.80% AAPL $348.91 +1.48% MSFT $530.14 -0.16% TSLA $403.30 -0.23% PLTR $196.42 -0.20% SOFI $17.61 +2.74% IBIT $43.36 -0.94% GLD $355.78 -1.34%